China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal

, , Comments Off on China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal

A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, …
( read original story …)